VEGFB (R125) polyclonal Antibody | BS1490

VEGFB (R125) polyclonal Antibody | BS1490 | Gentaur UK, US & Europe Distribution

Host: Rabbit

Reactivity: Human,Mouse,Rat

Application: WB IHC

Application Range: WB: 1:500~1:1000 IHC: 1:50~1:200

Background: The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth factor (FGF), platelet derived growth factor (PDGF) and vascular endothelial growth factor (VEGF) . VEGF is a dimeric glycoprotein with struc- tural homology to PDGF. Several variants of VEGF have been described that arise by alternative mRNA splicing. It has been speculated that VEGF may function as a tumor angiogenesis factor in vivo. Two additional proteins des- ignated VEGF-B and VEGF-C share a significant degree of homology withVEGF. VEGF-B is abundantly expressed in heart and skeletal muscle and is frequently co-expressed with VEGF.

Storage & Stability: Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Specificity: VEGFB (R125) polyclonal Antibody detects endogenous levels of VEGFB protein.

Molecular Weight: ~ 22 kDa

Note: For research use only, not for use in diagnostic procedure.

Alternative Names: Vascular endothelial growth factor B; VEGF-B; VEGF-related factor; VEGFB; VRF

Immunogen: Synthetic peptide, corresponding to amino acids 100-150 of Human VEGFB.

Conjugate: Unconjugated

Modification: Unmodification

Purification & Purity: The Antibody was affinity-purified from rabbit antiserum by affinity-chromatography using epitope-specific immunogen and the purity is > 95% (by SDS-PAGE) .

Pathway: Neuronal and Glial Cell Marker Atlas,Contribution of ECM and Cytoskeletal Factors to EMT,